Evidence is accumulating to indicate that the polyamines, spermidine (SPD) , spermine (SPM) are ubiquitously present in high concentrations in various tissues, including the brain, where they are synthesized from putrescine (1,4-diaminobutane) (PUT) (1-6) . It was also reported that hypothermia, anorexia, adipsia, changes in body weight and spon taneous motor activity were produced by the intraventricular injection of SPD and SPM to mice (7, 8) .
The intraventricular route of injection is the most appropriate for determining central actions of polyamines as there is the blood brain barrier against polyamines (9 , 10). The present investigation was an attempt to assess effects of SPD, SPM and PUT on sleep wakefulness in rats when these amines were injected directly into the brain .
MATERIALS AND METHODS

Subjects:
Male Wistar rats weighing 240-270 g were used at the beginning of the experiment. The animals were housed individually for the entire study period in plastic cages of 46x34,.,17 cm. Food and water were provided ad libitum under controlled enviromental conditions with a cycle of 12 hr light-12 hr darkness (9 a .m.-9 a.m.).
Surgery:
All animals were anesthetized with sodium pentobarbital (45 mg ,/kg, i.p.) and bipolar electrodes were chronically implanted into the occipital cortex, dorsal hip pocampus, neck muscle and the external canthus of each eye. These electrodes were made of enamelled stainless steel wire with a diameter of 200 g and were flattened at the end in contact with the dura mater in the case of implantation to the cortex. All electrodes were wired to a small connector fixed on the skull with dental cement. At the same time, a cannula slightly modified metal hypodermic needle (0.5 mm dia.) was also implanted into the left ventricle of each rat according to the brain atlas of Pellegrino and Cushman (11) . The position of the ventricle was verified histologically at the end of experiments by the injection of thionin blue just prior to sacrificing the animals.
Recording: Ten days after the implantation, each animal was placed in a sound proofed room, and EEG patterns were recorded using a NIHON KOHDEN multipurpose polygraph. The plastic cages were illuminated by a 20W bulb placed 1.0 meter above the center. The recording period was continued from 10:00 a.m. to 6:00 p.m..
Drug treatment: Drugs used were spermidine trihydrochloride (Nakarai Chemicals, LTD), spermine tetrahydrochloride (Nakarai Chemicals, LTD), putrescine dihydrochloride (Nakarai Chemicals, LTD) and pentobarbital sodium (Abbott). These were dissolved in pyrogen-free Ringer's solution and were given intraventricularly to the animals in a volume of 20 pl per animal with a graduated Hamilton syringe. After the administration of 20 leg and 40 leg of SPD, the percentage of wakefulness did not significantly change in any period observed (Fig. 2) . The administration in two doses of SPD did not produce a significant difference in the percentage of Non-REM sleep, either (Fig. 3) . Though the administration of 20 ,ig of SPD did not change the percentage of REM sleep, the REM sleep stage in rats given 40 ug SPD significantly decreased to 5.3 compared with 9.0% in control rats given Ringer's solution from the 24th to the 32nd hr after the administration of 40 leg of SPD (Fig. 4) . 
Effect of intraventricularly administered SPD and SPM oil total sleep
As shown in Table 1 Effect of intraventricularly administered PUT on wakefulness, Non-REM sleep, REM sleep and total sleep Immediately after the injection of 100 rrg of PUT to the 8th hr, the REM sleep pro nouncedly decreased to 1.5% without noticeable changes in Non-REM sleep and total sleep (Fig. 5) . From the 24th to the 32nd hr following administration of 100 pg of PUT, both Non-REM sleep and total sleep showed a significant decrease, though REM sleep tended to decrease slightly but not significantly. The amount of wakefulness , REM sleep, Non-REM sleep and total sleep returned to the normal in rats given Ringer's solution from the 72nd to the 80th hr.
DISCUSSION
The concentration of polyamines in mouse brain was shown to be higher in the pre natal and early post-natal life than in adults (12, 13) . In immature animals, the percentage of REM sleep increases while that of Non-REM sleep decreases. On the contrary, with maturation, the proportions of Non-REM sleep and REM sleep comprising total sleep alter, i.e., the percentage of time spent in Non-REM sleep increases while that of REM sleep decreases (14) . Our previous reports show that intracerebrally and intraperitoneally administered polyamines produce a prolongation of pentobarbital sleeping time in mice (8, 15) . However, there is no information concerning the relationship between exogenous polyamines and sleep-wakefulness cycles.
In the present communication, we observed that the administration of 40 ,ig of SPD decreased the REM sleep from the 24th to the 32nd hr and the same dose of SPM also markedly decreased both Non-REM sleep and REM sleep immediately after the injection of SPM to the 8th hr and from the 24th to the 32nd hr. As it was clear that the action of intraperitoneally or intracerebrally administered SPM was stronger than that of SPD in every case observed (8, 15) , the same result was also obtained in sleep-wakefulness;
the inhibitory action of SPM on Non-REM sleep and REM sleep was stronger than that of SPD. Theseresults stem partly from the observation that intraventricularly administered polyamines, particularly SPM, has central excitatory actions, i.e., high doses of polyamines produce convulsion, paralysis and erection in emaciated mice (8).
Anderson et al. (7) reported that polyamines produced necrotic lesions in the brain stem and spinal cord in mice which had been injected 5 days previously with 50 beg of SPD.
We also observed lesions in the thalamus of rats and in the pons of mice (unpublished observation). There is no possibility that the inhibition of sleep in rats administered poly amines was due to lesions in the brain, as a few days at least are required before such lesions occur and the decrease in sleep usually recovered to normal levels 2 days after polyamines.
In our recent experiment, the dose of polyamines used in sleep studies induced anorexia which disappeared in approximately 2 days (unpublished observation). The effective period of intraventricularly administered polyamines on sleep-wakefulness cycles was similar to that on food intake in rats. It seems likely, therefore, that the hyposomnia induced by the injection of polyamines reflects a direct action on the central nervous system or changes in brain monoamines and other active substances.
Halliday and Shaw (16) observed that following the intracerebroventricular injection into rabbits of SPD or SPM, the highest concentration was initially found in the caudate nucleus, hypothalamus and medulla. The concentrated site of polyamines was assumed to play an important role in not only the changes in sleep-wakefulness cycles, but also other actions.
In the present investigation, it was shown that the intraventricular injection of PUT produced changes in sleep-wakefulness cycles which were quite similar to those that follow the intraventricular injection of polyamines. This finding indicates that the intraventricular injection of PUT led to accumulation of SPD and SPM in the rat brain. However, though
PUT is the precursor of SPD and SPM in the brain (9, 17) , a degradative pathway, based on in vivo studies, involving the formation of GABA has been suggested (18) . It must be fully considered that the administration of PUT evoked not only the increase of SPD and SPM but also the formation of GABA in the brain (19).
Little is known of the metabolic fate of SPD or SPM. Putreanine, N-(4-aminobutyl)
3-aminopropionic acid, found in mammalian brain but not in other organs, appears to be a catabolite of SPD (20). And spermic acid, N,N'-bis (2-carboxyethyl)-1,4 diaminobutane, isolated from bovine brain has been postulated to be the deamination product of SPM (21).
The precise degradation of PUT involving the formation of polyamines and GABA, and the clear catabolism of polyamines as determined in biochemical studies should serve to demonstrate the action of polyamines in the pharmacological field.
